Bibliothek

X
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • 2000-2004  (4)
  • Quality of life  (2)
  • metastatic breast cancer  (2)
  • 1
    Digitale Medien
    Digitale Medien
    The Effects of Type of Surgery and Time on Psychological Adjustment in Women After Breast Cancer Treatment (2000)
    Springer
    Annals of surgical oncology 7 (2000), S. 427-434 
    Details
    ISSN: 1534-4681
    Schlagwort(e): Breast cancer ; Quality of life ; Mental health ; Surgery
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Background: The aim of the present study was to examine whether type of surgery, age, and time since surgery influenced psychological distress and quality of life (QOL) in women treated for breast cancer. Methods: We surveyed 183 women who had undergone surgery for breast cancer. Psychological distress was measured with the Mental Health Inventory and QOL was measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Results: After controlling for stage of disease, radiation treatment, and age, there was a statistically significant interaction between type of surgery and time since surgery for the Mental Health Inventory total score, and a marginal interaction between type of surgery and time since surgery for the Global health status/QOL score. Women who had breast conservation surgery experienced significantly greater levels of psychological distress and marginally worse QOL from 40 months after surgery onward than did women who received a mastectomy. Conclusions: The effects of different surgical treatments for breast cancer on psychological distress and QOL become apparent only after a period of several years. Women, therefore, need counseling on the potentially positive and negative psychological implications of different surgical treatments for breast cancer.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/s10434-000-0427-9
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 2
    Digitale Medien
    Digitale Medien
    Liarozole Fumarate (R85246): In the Treatment of ER Negative, Tamoxifen Refractory or Chemotherapy Resistant Postmenopausal Metastatic Breast Cancer (2000)
    Springer
    Breast cancer research and treatment 64 (2000), S. 177-188 
    Details
    ISSN: 1573-7217
    Schlagwort(e): aromatase inhibitor ; hormone independent ; liarozole ; metastatic breast cancer ; RAMBA
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Three phase II studies were conducted to determine the efficacy and tolerability of liarozole fumarate (R85246; liarozole), a retinoic acid metabolism blocking agent (RAMBA) and aromatase inhibitor. Additionally, animal experiments in the MNU-induced rat mammary tumor model and in immature ovariectomized rats were conducted to further elucidate liarozole's mechanisms of action. Patients were postmenopausal with either: ER negative disease in first relapse (Group 1; n = 16); ER positive or unknown disease refractory to tamoxifen (Group 2; n = 16); ER positive, negative or unknown disease resistant or refractory to chemotherapy (Group 3; n = 27). Treatment was liarozole (150–300 mg) twice daily orally until disease progression. Response rates were: 25% in group 1 (95% CI 11.0–52.3%; median duration (MD) 20 months; range 2–36.5); 25% in group 2 (95% CI 11.0–52.3%; MD 6.5 months; range 3.5–38); 11% in group 3 (95% CI 4.2–29.2%; MD 7 months; range 3–8.5). No significant improvement in quality of life scores (FLI-C) was noted. Toxicities observed were predominantly dermatological (skin disorders: 88%; dry mouth/eyes/lips: 69%). Plasma estradiol decreased from mean pre-treatment levels of 72.7 pM (9.1–1839 pM) to below detection (9.2 pM) after 1 month. Liarozole, but not vorozole, partially inhibited estradiol induced uterine hypertrophy and demonstrated dose-dependent anti-tumor effects in the rats, only partially overcome by coadministration of estradiol. The clinical responses observed, together with our preclinical results, confirm liarozole's dual mechanism of action and provide a rationale for further evaluation of RAMBAs in the treatment of breast cancer.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1023/A:1006480504790
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 3
    Digitale Medien
    Digitale Medien
    Health values of patients with bipolar disorder (2000)
    Springer
    Quality of life research 9 (2000), S. 579-586 
    Details
    ISSN: 1573-2649
    Schlagwort(e): Bipolar disorder ; Health status ; Mental health ; Outcome assessment (health care) ; Quality of life
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Background: Despite a growing number of studies of patients' health values (utilities), little is known about health values of patients with mental illness, particularly bipolar (manic-depressive) disorder. Methods: We administered a computerized rating scale, time tradeoff, and standard gamble to 53 patients. Patients were asked to rate or value their current state of health overall and then their current mental health. In addition, we administered the SF-36; Inventory of Depressive Symptoms (IDS-C); Positive and Negative Syndrome Scale (PANSS); Young Mania Rating Scale (YMRS); and Global Assessment of Functioning Scale. Results: The patients' median (25th, 75th percentile) age was 43 (37, 50); 62% were female. Mean (±SD) health ratings for current overall health were 68.0 (±20.3) vs. 61.0 (±25.7) for current mental health (p-value for difference = 0.02). On the time tradeoff, scores for current overall health averaged 0.71 (±0.37) vs. 0.61 (±0.39) for current mental health (p = 0.02); on the standard gamble, mean scores were 0.77 (±0.32) for current overall health vs. 0.70 (±0.35) for current mental health (p = 0.11). In univariate analyses, rating scale, time-tradeoff, and standard gamble scores for both current overall health and for current mental health were correlated with the SF-36 and all psychiatric scales (|r| = 0.22–0.76) except the YMRS (|r| ≤ 0.13). In multivariable analyses, health values for current overall health were related to factors different from those that were related to health values for current mental health (R 2 = 0.38–0.65), and none of the health value measures was related to the YMRS. Conclusion: Health values of patients with bipolar disorder are higher for their current health overall than for their current state of mental health. Health values are related to certain health status attributes and to level of depression but perhaps not to level of mania.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1023/A:1008979825704
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 4
    Digitale Medien
    Digitale Medien
    Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer (2000)
    Springer
    Breast cancer research and treatment 59 (2000), S. 55-68 
    Details
    ISSN: 1573-7217
    Schlagwort(e): liarozole ; metastatic breast cancer ; postmenopausal
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evaluate quality of life. Twenty-nine women with ER-positive or unknown metastatic disease who received ≥ 2 prior hormonal therapies were treated with 150–300 mg liarozole twice daily until disease progression. All patients were evaluable for toxicity and 25 for response. Four patients (16.0%, 95% CI 5.3–37.4%) had partial remission (PR) of their disease for a median of 7.4 months (range 1.2–12.9) and 7 (28%) had disease stabilization for a median of 4.8 months (1.6–16.0). Estradiol decreased from pre-treatment levels of 9.2–52 pM (mean 17.1) to below detection (9.2 pM, p=0.0005) after 1 month. Similarly estrone levels fell from 14–307 pM (mean 92.7) to below detection (9.2 pM, p=0.0001). The most common toxicity was dermatological (96.6%) with features compatible with hypervitaminosis A syndrome such as rash, pruritus, dry skin, and brittle nails. The majority of these were mild to moderate in severity. No significant improvement in quality of life scores (FLI-C) were noted. Liarozole is an active new treatment for breast cancer in patients heavily pre-treated with hormone therapies. Further studies are needed to confirm its relative efficacy in both receptor positive and negative postmenopausal breast cancer.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1023/A:1006320122711
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...